The toolkit is already astonishing. We can read the entire genome of a single cell. We can edit DNA with a kind of molecular search-and-replace. We can skip DNA entirely and hand a cell a temporary mRNA program, the trick behind the COVID vaccines. We can even flip the epigenetic switches that decide what job a cell does, for example coaxing a skin cell to become a nerve cell. These tools reach into a cell far more powerfully than any pill - unlike drugs, that generally just modulate the activity of your existing biological machinery, with bioengineering we can add entirely new capabilities. In principle, new genetic programs could let us break down or excrete the junk that clogs aging cells, rebuild worn-out extracellular components of tissue, borrow cancer resistance and other “superpowers” from elephants, whales and other species, and even make ourselves completely immune to viruses. These are not science fiction, but real projects at various stages of development.

So are we on the cusp of solving aging through bioengineering? So far the answer is no, what’s doable in a lab setting is not so easy to translate into therapies for living humans. There are two enormous barriers (we’ll call them “walls”) to surmount for radical life extension to be achieved through bioengineering, design and delivery, which we’ll delve into below. On the other hand, intermediate levels of progress buy us time, and there are strategies that can make the problem somewhat easier. First, we don’t need to chase down solutions to every aspect of diseases of aging, instead we can target the upstream age-related damage that causes those diseases. That’s called the Geroscience Hypothesis, and it means that when it comes to aging, you can feed multiple birds with one scone. We can also make things easier by mostly staying downstream of normal metabolic processes and instead focusing on repairing the damage that they cause. Repairing damage should generally be safer and easier than preventing it, because you are risking disturbance to your body’s natural homeostasis by attempting to reinvent it. These are not hard rules, in some cases modifying metabolic processes might be the easier solution, such as increasing DNA replication fidelity, but in most cases targeting damage appears to be more feasible in the near term.

What already works

While the walls must be scaled to achieve complete solution to aging, there are plenty of partial wins already in progress.

• CAR-T: a patient’s own immune cells are re-engineered to hunt cancer. Already approved and saving lives, it is proof that engineered cells can do remarkable work.

• CRISPR-based gene editing: results are starting to arrive. For example, Casgevy has shown over 90% success in treating sickle-cell disease.

• Non-integrating “Episome” gene therapies: working genes can now be given to patients. For example, Hemgenix infusions have shown long-term remission of hemophilia B.

• siRNA: small-interfering RNA molecules can be given to patients to block harmful molecules from being produced. Patisiran suppresses transthyretin, which appears to be a very effective treatment for neuropathy. Inclisarin blocks the production of the protein PCSK9, leading to lower risk of cardiovascular disease through lowering of the blood lipids that cause it.

• New gene circuits: gene therapies targeting the liver have shown promising results for reversing atherosclerotic plaques.

Many more interesting and more powerful therapies are at various stages ofclinical and pre-clinical stages of development. This next generation could help people live longer than expected and, hopefully, long enough to live forever.

With all this going for us, why isn’t aging solved? Because bioengineering runs into two enormous walls.

Wall one: the design problem

The truth is that we don’t actually know what changes to make to cure aging. We have some ideas for how to improve things, sure. Fix point mutations, change genes to longevity-associated alleles, upregulate repair, tumor suppression, and other protective genetic pathways. Unfortunately, that’s not even remotely enough to solve aging.

It’s tempting to assume we’ve mostly figured out human biology based on the sheer volume of academic literature. We haven’t. Of our roughly 20,000 protein-coding genes, we have a decent understanding of only about a fifth of them. And most genes don’t even make proteins; they make RNA molecules we understand far less. Zoom out to how genes interact with to each other, and the map is mostly blank. The unknowns in biology dwarf the knowns.

Now remember that aging isn’t one broken gene. Reversing it will likely require not a few tweaks but new genetic programming on a massive scale. This potentially means thousands of new genes and edits, each of which has to do its job and get along with all the others. Even if you have a promising design (in the lab), how do you know if and by how much it will extend lifespan in reality? Right now this is determined empirically, first by testing the design in model systems like animals, and then clinical trials, a process that takes decades. What if you have two promising designs, but it turns out that in practice they interact negatively, nullifying any benefit or even damaging the patient. Now multiply this slow process by the hundreds or thousands of edits you need to make, the countless combinations of possible interactions, and the decades to test each. This is the design problem, and it is the deepest wall in the field.

Wall two: the delivery problem

Even if we knew exactly what to change, with current technology we couldn’t make the changes everywhere they need to happen.

If all your cells were grains of sand, they’d fill an Olympic swimming pool. Now try to put one dot of paint on every single grain. Spray from the top and the bottom gets nothing; flood the pool and the top gets too much. That’s the current state of gene delivery. It’s easy to edit a cell in a dish, yet almost indescribably hard to get the right edits, in the right doses, into all the trillions of cells in a living adult.

Today’s delivery vehicles such as viruses or lipid nanoparticles are limited to payload sizes smaller than many single genes (let alone complex genetic circuits), often provoke the immune system and/or are toxic except in very small doses, and fail to distribute evenly throughout the body. Delivery is not just holding up the big ideas that will solve aging, but even most of the simple ideas we already have. Take the gene variant ApoE4, which causes early onset Alzheimer’s Disease - we’ve known about it for over three decades, but our primitive gene delivery technology cannot fix it. Solve the delivery problem and an armada of new gene therapies could rapidly be brought to the market.

The honest timeline

Bioengineering has no roadmap and barely even a sketch of what one might look like. Rough guesses for a complete solution to aging range from five years (counting on vastly more powerful AI), to over a century because even with AI there is real world friction in data collection and trials that have to run at “normal time”. Some problems like the accumulation of DNA mutations and chemical damage to the extracellular matrix have essentially no plausible proposed solutions on the horizon - it’s easy to be pessimistic.

However, not having a complete solution soon doesn’t mean having nothing. Progress comes in phases: first simple therapies that fix a few specific problems, then optimized genomes that make living to 100 ordinary, then eventually the deep genetic software upgrades that push past the natural limits to human lifespan. People reliably overestimate what can be achieved in a few years but underestimate what will be achieved in a few decades. The last few decades gave us CRISPR gene editing out of nowhere. The next few will hopefully surprise us too.

Where you come in

Bioengineering is ripe with opportunity. It is already the best-funded part of the whole longevity field, with enormous quantities of money and talent from the broader biotech world pouring into gene editing, delivery, and reprogramming. The question isn’t how can we do more, but rather how do we focus time and attention on the right work:

• If you’re a scientist, the deepest wall is design: the biology we still can’t read. Work on how genes function and how they talk to each other. Develop better and cheaper data collection, computational models, and faster ways to validate designs.

• If you’re an engineer, delivery is the bottleneck gating nearly every therapy: better vehicles to get the right edit into every cell would unlock an armada of them. Don’t work on incremental changes to existing approaches, think out of the box. How could safe and efficient head to toe genetic software updates be delivered?

• If you’re a builder or funder, you’ll have your pick of indications and a growing stack of technology platforms: pick a root cause of aging and get a solution to market.

• If you’re in government or policy, redirect more funds to fundamental aging biology and hard technology development that private funders are too risk averse or short-termist to touch.

• If you’re in AI, help develop models optimized for biology, and (perhaps in collaboration with government) put as much funding as you can towards the deep and extensive biological data that will be needed to train them.

Whatever you choose, the goal is the same: developing technologies that repair age-related damage and thereby extend human lifespan. These technologies will cure age-related disease, but don’t lose the forest for the trees. Curing aging, the underlying cause, is the ultimate goal and ultimate prize. Given our current understanding of biology, this seems certain to happen eventually. What is uncertain is when.

So don’t be content to wait. Dedicate time to moving the field faster. Find an area you like and jump in so we can make these lifesaving technologies available as soon as possible.

Therapeutic replacement aims to solve aging by replacing aged tissues and organs with young ones. Instead of trying to understand every type of aging damage and repair it with a new drug, you can replace all types of damage at once. It doesn’t matter if a patch of skin is burned, infected, or cancerous; swap in new skin and all three problems vanish. This is important because aging is a combination of many types of damage, including types we don’t understand or haven’t even identified - replacement can solve all of them simultaneously with a single therapy.

So why aren’t we already using it to reverse aging? The biggest reason is supply constraints. Almost all replacement organs come from donors, and there are nowhere near enough to treat acute diseases, let alone aging. People wait years on lists; most never get the call. As long as organs are scarce, we need to ration them for the desperately sick.

Cells can be manufactured at scale, and used to great therapeutic benefit, however they sit in a scaffold of long-lived molecules called the ECM, and it ages too. It would be convenient if we could fully rejuvenate the body with cell therapies, but without major bioengineering breakthroughs in ECM repair, tissue-level replacement is the most feasible way to handle ECM aging.

But things would change if supply were unlimited. Suddenly the whole logic flips. You don’t wait for stage-5 kidney failure; you replace the kidney at stage 3, or give an aging-but-healthy person young organs before the heart attack instead of after. Medicine stops being reactive and becomes proactive. If you replace some tissues and organs, you may delay the onset of age-related disease. Replace enough and they may never occur at all. That is the world replacement is trying to build.

What already works

Replacement isn’t even a new idea. It’s already one of the most successful categories of medicine we have. Blood transfusions, artificial hips, and organ transplants are all replacement, all routine, all saving lives every day. When doctors don’t understand a liver disease, or don’t have a drug to treat it, they fall back to replacement.

A few example of replacement procedures already available, spanning every biological scale:

• Organelles: healthy mitochondria can be transplanted into damaged tissue. In one trial, 8 of 10 critically ill children with heart damage were weaned off heart-lung life support after a mitochondrial transplant.

• Cells: blood stem cells, immune cells, and new cell therapies for the heart, brain, and eyes are in the clinic or close to it.

• Organs: hundreds of thousands of transplants happen every year, and when the donor is younger than the patient, the patient gets a little bit younger too.

The frontier is moving fast. A company called Humacyte just earned the first-ever FDA approval for a lab-grown blood vessel, proof that engineered human tissue can go all the way through the regulator to real patients. Genetically-edited pig organs have kept primates alive for a couple of years. And the U.S. government’s health-innovation agency is now funding a serious program aimed at replacing damaged brain tissue after stroke.

Where this is going: bodyoids, body transplants, and the brain

The endgame of the supply problem is to grow and unlimited supply of replacement parts instead of waiting for donors. The trick to achieving this is counterintuitive: a single organ is hard to grow in a jar, because organs are a team. The kidney expects the heart to pump and the lungs to breathe for it, so if you try to grow it alone you must artificially substitute all the functions of all the other organs. But if you grow most or all the organs together they can support each other, just like they evolved to. Grow enough of them and you approach what’s called a bodyoid: a young body, with organs, limbs, and blood, but deliberately engineered with no brain, so it can never become a person.

With a supply of young parts, the delivery question becomes surgical. And the surgery has a natural sweet spot: rather than transplant a dozen organs one at a time, you keep the patient’s head and give them a new body from the neck down. This is called a body transplant, and it has been tested to some extent in the lab, showing that the circulatory system of a new body can keep a head alive in various animals. Not only that, but cleanly cut spinal cords have been fused back together in animals that then learned to walk again. So while replacement bodies and the surgery to transplant them do not yet exist, we are seeing promising early signs that this technology could become reality.

That leaves the hardest and most personal part: the brain. The brain can’t be replaced all at once like a kidney because that would kill you. Instead, it must be replaced slowly, a small piece at a time, letting the brain’s natural ability to shift functions around (neuroplasticity) carry you through. It’s like the Ship of Theseus, replaced plank by plank while still sailing. Nobody has a finished answer here but the hope is that cell replacement, tissue replacement, or some combination can help keep the brain young and healthy.

The honest hard parts

Replacement has great potential, but it isn’t a silver bullet. There are several challenges that need to be addressed:

• Supply: everything downstream waits on our ability to produce young cells, tissue, and body(oids) at scale. This is the most immediately limiting bottleneck and perhaps most readily solved.

• Surgery: big transplants carry real mortality risk, which is why automated, robotic surgery matters so much.

• Immune Tolerance: new parts must not be rejected. Newer techniques, like giving a bit of the donor’s bone marrow along with the transplant, are making off-the-shelf, drug-free compatibility look achievable, but we do not yet have a universal solution.

• Brain Integration: normal brain growth happens in parallel, with all parts growing and forming connections following a genetic developmental program. Brain replacement needs to reproduce the formation of connections but between tissues of varying age (young naive tissue integrating with older mature tissue).

This may sound like a long, hard road, but the path is at least clear. The only question is how quickly we can make our way along it.

Where you come in

Aging is the most complicated problem in biology. Replacement is a shortcut around slow and expensive work to understand and repair it molecule by molecule. That is why, if it works, it will be the fastest path to defeating aging.

The obstacles are mostly engineering: supply and delivery. Engineering problems fall to money and effort, not to a lucky scientific miracle we can’t schedule. Work here will likely have real and substantial payoff.

• If you’re a scientist or engineer, the highest-leverage work is on the supply side: growing organs, organ networks, and ideally bodyoids, plus the incubation and life-support systems to manage them.

• If you’re a roboticist,surgeon or AI engineer, automated transplantation is the only way this ever reaches everyone. Help develop autonomous systems that make replacement safe and scalable.

• If you’re a neuroscientist or neuro tech builder you can help with pre-clinical studies on brain tissue replacement, including developing methods for ensuring tissues connect properly.

• If you’re a builder or funder, the industry is young and wide open. Near-term therapies (better microbiome, blood, mitochondrial, and ECM treatments) are already ready to commercialize, and many existing startups and new ones must be built and funded to solve the hard technical challenges .

Replacement is, at heart, a conceptually simple idea: replacing organs is often easier than curing disease. The obstacles are real, but they’re the kind we know how to knock down. So pick one, and help strike a mortal blow against aging.

Biostasis applies the same idea to the terminally ill. We may not have the technology to cure someone’s cancer now, but it seems probable that we will in the future. If their biological processes could be paused until then, they might be saved by future medical technology. Biostasis uses cold temperatures, chemicals, or both to put people into metabolic arrest so that their bodies will not degrade over time. This is not guaranteed to save them but, unlike burial or cremation, it gives them a chance.

Biostasis is a real service that can be purchased today. It’s a good thing, too, because the uncomfortable fact is that some of the people we care about (and maybe even all of us) are going to run out of time before aging is solved. Aging is a hard problem, and a real cure is going to take longer than many people can wait. So what do you do for someone whose clock is running out? You buy them time with biostasis.

The idea is simple. When modern medicine runs out of options, we preserve a patient’s body well enough that a future doctor, with future technology, might be able to bring them back. Cold does most of the work because, below a certain temperature, biology essentially stops. Molecules stop moving, decay stops happening, and a person can wait, unchanged, for a very long time. A hundred years in that state might age you about as much as a single minute of ordinary life.

If that sounds like science fiction, consider that a shorter version is already routine medicine. Surgeons sometimes cool a patient until the heart can be safely stopped, operate, and then rewarm them back to life. There is a saying among emergency doctors: you’re not dead until you’re warm and dead. Biostasis takes that same principle and stretches it from minutes to centuries.

What actually happens today

A patient signs up in advance, usually with a cryonics organization. When the patient is nearing death, a standby team is deployed to wait at their bedside. The moment they’re declared legally dead, the team goes to work: cool the body fast, keep the blood vessels open, and pump in a protective antifreeze solution called a cryoprotectant. Later at a storage facility, the patient is cooled to liquid nitrogen temperature. Done well, the patient doesn’t freeze into ice. Instead, they enter a glass-like state called vitrification. They are then stored in an insulated container called a dewar that requires no electricity, just a little liquid nitrogen to be added occasionally to keep the patient cold.

We do not currently have the technology to reverse this process and safely warm someone back up. We can only do our best getting someone into stasis so that future revival is as easy as possible. To improve the preservation process, some biostasis organizations check their work by running CT scans of vitrified brains and taking tiny tissue samples to look at the structures under a microscope. Under good conditions, the current techniques seem to preserve all the important parts that make up who you are: nerves, axons, and even synapses.

Biostasis is something that needs to be arranged in advance, so don’t wait until someone you care about is declared dead before you contact a provider. And don’t assume you can wait until you are old to sign up, because aging isn’t the only thing that can kill you.

Improving the process

Right now, biostasis is a bet on the future. We can reliably rewarm cells, thin sections of tissue, and small organs, but nothing as large as a human brain. Work is currently ongoing to vitrify and rewarm entire small mammals and larger organs like pig kidneys.

To make progress, new technologies are needed. The major focus of research is developing improved cryoprotectants. People are working on novel chemistry, biological research, thermodynamic models, and molecular simulations to predict how best to protect people during the cryopreservation and rewarming process. A perfect cryoprotectant would not only make it easier to get people into biostasis, but make it much easier to rewarm and revive a patient. Groups advancing this technology include 21st Century Medicine, Until Labs, Vitrify.ai, and Maximize Bio.

In addition to creating better cryoprotectants, some people are looking into revival technologies. This includes direct methods of warming up a patient, such as ultrasound, and also indirect methods like perfusing nanoparticles that can be vibrated with magnetic fields. This research is still very early but, fortunately, patients in biostasis have time on their side. While some approaches require pre-conditioning the patient before biostasis, such as the perfusion of nanoparticles, others like ultrasound re-warming do not. This means that while the chances of you being revivable will increase the longer you can wait to be put in biostasis, even now there is a chance.

So while biostasis is far from a mature technology, it is still a rational approach to the problem. If you want to live, but you’re going to die, then die in the most reversible way possible.

The honest hard parts

While it seems that the technologies used for preservation today do a good job of preserving the information content of the brain so that it is theoretically possible to revive someone, the current process does not keep a brain viable by today’s standards. Overcoming the obstacles to present-day viability is a real challenge for a few reasons.

• Toxicity: modern cryoprotectants are toxic. They prevent ice crystal formation, but they do some biological damage to cells in the process, for example by dehydrating tissues. Creating non-toxic cryoprotectants would make it much easier for future doctors to revive patients. Reducing the exposure to the toxic effects by faster perfusion and clearing of them, complementary approaches to protect the body from them, or enabling cells to produce and degrade them on demand would also reduce toxicity.

• Fractures: cooling a patient to liquid nitrogen temperatures prevents metabolic damage, but it also puts them at risk of crack formation. Cracks could make revival difficult, especially if they occur in the brain, so techniques for avoiding fractures are needed.

• Perfusability: it is sometimes difficult to get cryoprotectants to every part of the body. Making them easier to perfuse would help ensure that the patient is fully protected.

There are also operational, social and regulatory challenges. Biostasis is a type of emergency medicine, and the field is still small. This makes it difficult to provide coverage and high-quality service to everyone who might want it. Improved logistics and regulation are needed to make biostasis available, and this will grow in importance as the technology matures, especially after reversibility is demonstrated...

The bad news is that very little money and talent are directed to biostasis. The good news is that there is still a lot of low-hanging fruit. A modest amount of funding or a few good people can move this field in a big way that would be impossible in many other industries.

Where you come in

You don’t need a PhD to matter here. The to-do list is long and much of it is wide open:

• If you’re technical, the highest-leverage work is creating better cryoprotectants or other pre-conditioning approaches to enhance the quality of biostasis preservation. Faster and more even re-warming technologies are important too..

• If you’re an operator or entrepreneur, the industry needs better logistics, better standby coverage, and businesses that make good preservation available to more people in more places.

• If you’re none of those, spread the word. Every person who signs up is a life that might be saved, and every new member makes the whole system cheaper, safer, and more socially acceptable for the next person. Advocacy and marketing can go a long way in cryonics.

Most people call biostasis “Plan B.” But for radical life extension, ask people what Plan A is and watch them realize they don’t have one. Today, biostasis is Plan A for everyone, regardless of their age. That may change in the decades to come, but for now we should all care deeply about and support advances in biostasis, since there is a good you or someone you care about will need to use it.

The Longevity Biotech Fellowship maintains a technology roadmap to change that. It lays out alternative paths to traditional pharma and biotech, ones that could genuinely solve aging, not merely delay it by a few years. This roadmap is meant to point talent and funding at the highest-impact opportunities.

Four ways to face aging

Every approach to aging answers two questions. First: do you need to understand aging to beat it, or can you bypass that complexity entirely? Second: are you trying to solve aging outright, or just buy time until we can? Those two questions make a map.

Three of these quadrants are the high-impact strategies the roadmap champions. The fourth is where most of today’s field already sits.

The three primary strategies

Bioengineering: understand aging, then solve it. Re-engineer our own biology to repair the damage that drives age-related disease. The upside is the most complete and scalable answer imaginable, a cure that could one day fit in a routine injections or pills. The catch is that this is by far the hardest and least-understood path, with wildly uncertain timelines for a full solution. On the other hand, incremental progress might lead to “longevity escape velocity”, but we have not yet hit the elbow of that curve and don’t know when we will.

Replacement: bypass the requirement to understand aging, and still solve it by simply replacing old parts with young ones grown in the same way as nature. The upside is that it sidesteps the crushing complexity of aging and the surprisingly daunting challenge of even knowing if your therapies work, and looks like the nearest and cheapest (potentially) complete solution. The catch is that it needs a supply of young tissue, advances in surgery, and the one part you cannot simply swap out is the most important: the brain.

Biostasis: the ultimate approach to “buying time”. Preserve people who are out of options today, to be revived in the future when better medicine can restore them to perfect health. The upside is that it is the only strategy available right now, and a source of hope for those who cannot wait. The catch is that we cannot yet reverse it; for now it is a bet that the future will finish what we start.

The fourth quadrant, low-impact therapies, is the drugs and single-disease treatments that most of the field works on. They have real near-term value but small effect sizes: they might slow aging and even add a few years, but even many of them combined would never come close to solving aging, or even shifting maximum lifespan by much. That is why the roadmap points elsewhere.

Why the strategies are stronger together

We do not know how each of the strategies will play out, what they will take to implement, and how long it will be before we can verify that they work. However, it is likely that many people will need some combination of the technologies from each category, so these are not competing bets. They compound.

• Bioengineering makes the other two work better. The same tools that repair aging damage also give biostasis better cryoprotectants and other tools for reversible preservation, and give replacement better-engineered tissue,drug-free immune tolerance, and tools to help enable or complement gradual brain replacement.

• Replacement lets bioengineers attack the hardest problem. If you can replace the body from the neck down, the field’s sharpest minds can concentrate their repair work on the one thing you cannot replace outright: the brain.

• Biostasis is everyone’s lifejacket. If a body transplant or a bioengineering cure is not ready in time, biostasis buys the years needed for it to arrive. It catches the people the other paths cannot reach in time.

Together they form a portfolio: parallel routes to the same destination that de-risk each other, so a stall on any single path does not doom the mission.

Where you come in

No one is coming to solve this for us. The roadmap is only as fast as the people working it, and the biggest bottleneck today is not which strategy to pick, it is that far too few people are working on any of them.

That is the whole point of the Longevity Biotech Fellowship. Whether you are a scientist, an engineer, an entrepreneur, or a funder, there is high-leverage, wide-open work waiting on every one of these paths. Join the fellowship and help us create a world where aging is a thing of the past.